|Bid||9.80 x 800|
|Ask||10.33 x 800|
|Day's Range||9.89 - 10.28|
|52 Week Range||7.91 - 70.98|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.67|
NEW YORK, Nov. 22, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980. The investigation concerns whether NextCure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On January 13, 2020, NextCure disclosed in a U.S. Securities and Exchange Commission filing that Eli Lilly and Company had ended its 2018 research and development collaboration agreement with NextCure. On this news, NextCure’s stock price fell $4.70 per share, or 8.29%, to close at $52.00 per share on January 13, 2020. Then, on July 13, 2020, NextCure issued a press release announcing that the Company no longer planned to “advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial” for its NC318 immunomedicine product, citing “clinical response data” and “current enrollment criteria.” NextCure concurrently announced the resignation of Kevin N. Heller from his role as the Company’s Chief Medical Officer. On this news, NextCure’s stock price fell $9.73 per share, or more than 54%, to close at $8.15 per share on July 13, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP email@example.com 888-476-6529 ext. 7980
NEW YORK, NY / ACCESSWIRE / November 20, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the securities of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company's Registration Statement on Form S-1 which was filed with and declared effective by the SEC on November 12, and November 14, 2019. The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.